<DOC>
	<DOC>NCT00038636</DOC>
	<brief_summary>The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir</brief_summary>
	<brief_title>A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion: HIV positive Are at least 18 years old Subject has not been treated for an active AIDSdefining opportunistic infection within 15 days of screening HIV RNA level &gt; 1000 copies/mL Previous therapy with at least one protease inhibitor, at least one nonnucleoside reverse transcriptase inhibitor and at least one nucleoside reverse transcriptase inhibitor Exclusion: Subject is pregnant or breastfeeding Subject has received an investigational drug within 30 days prior to screening Have a history of pancreatitis History of intolerance to ritonavir Abnormal laboratory tests at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>HIV</keyword>
</DOC>